• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of all recall classifications meeting 26 calendar-day timeframe in the month

Dictionary: Using the recall process, manufacturers may voluntarily remove a drug from the marketplace if a drug quality defect is found. OC classifies the recall (or recommends classification in some cases) based on the level of public health risk. A Class I recall is the most significant recall. A recall may be done for a single product dosage form or for multiple dosage forms, or multiple products.

Information is current as of December 31, 2013.

Fiscal Year - 2013

Skip graphic and jump to text data

TimeTargetPercentage
Oct 20128593
Nov 20128596
Dec 20128584
Jan 20138094
Feb 20138587
Mar 20138572
Apr 20138591
May 20138590
Jun 20138587
Jul 20138589
Aug 20138588
Sep 20138596

FY 2013 Overall: 89%

Footnotes

  • CDER created new measures and began collecting data in July 2012. Therefore, FY12 will only include 3 months of data.

Percentage of Class I classifications meeting 26 calendar-day timeframe in the month

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetPercentage
Oct 201290100
Nov 20129083
Dec 2012900
Jan 201390100
Feb 20139083
Mar 201390N/A
Apr 201390100
May 201390100
Jun 201390100
Jul 201390100
Aug 201390100
Sep 201390100

FY13 Overall: 93%

Percentage of Class II classifications meeting 26 calendar-day timeframe in the month

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetPercentage
Oct 201285100
Nov 201285100
Dec 20128592
Jan 201385100
Feb 20138579
Mar 20138572
Apr 20138582
May 20138592
Jun 20138588
Jul 20138586
Aug 20138583
Sep 20138595

FY13 Overall: 88%

Percentage of Class III classifications meeting 26 calendar-day timeframe in the month

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetPercentage
Oct 20128075
Nov 201280100
Dec 20128080
Jan 20138083
Feb 201380100
Mar 20138073
Apr 201380100
May 20138082
Jun 20138083
Jul 20138090
Aug 20138092
Sep 201380100

FY13 Overall: 88%

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.